Novel ion channel approaches to reentrant arrythymias
治疗折返性心律失常的新型离子通道方法
基本信息
- 批准号:8475498
- 负责人:
- 金额:$ 73.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-15 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAccountingAction PotentialsAdenovirusesAdultAffectAnimal ModelAnimalsArrhythmiaCanis familiarisCardiacCardiac MyocytesCathetersCell LineCell TherapyCellsCessation of lifeClinical TrialsComputer SimulationCoronaryDevicesEngineeringFrequenciesFunctional disorderGenerationsGenesGeneticGoalsHeadHealthHeartHeart RateHumanIn SituIn VitroIndividualInfarctionInterventionIon ChannelIonsKineticsKnowledgeLeadLigationMembrane PotentialsMesenchymal Stem CellsModalityModelingModificationMorbidity - disease rateMuscle CellsMutateMyocardial InfarctionOutcomePathway interactionsPatientsPharmaceutical PreparationsPreventionPrevention therapyPropertyRefractoryResearchSiteSite-Directed MutagenesisSpecificitySpeedStressSystemTailTechniquesTestingTextTissuesVentricularVentricular TachycardiaViralViral Vectorbasedensitydesigngene therapyimprovedin vivoinnovationmathematical modelmortalitymutantnovelnovel strategiesoverexpressionprematurepreventresearch studystatisticssudden cardiac death
项目摘要
DESCRIPTION (provided by applicant): The overall objective of our proposed research is to use our knowledge of the pathophysiology of reentry and of myocardial infarct-associated ventricular tachycardia to hypothesize innovative, mechanism-based approaches to therapy Our general hypothesis is that gene therapy using adult human mesenchymal stem cells (hMSCs) as platforms and/or using viral vectors can deliver overexpressed ion channel gene constructs to prevent/suppress this arrhythmia. Our proposed 5-year plan incorporates: (1) identification and testing the effect of overexpression of specific gene constructs in viral vectors and in hMSC platforms to modify specific ion channel expression in cell lines; (2) using mathematical modeling, cell systems, and animal models that previously have been validated by us and others to test the mechanism of action, efficacy and proarrhythmic potential of each gene and cell therapy approach we design. We specifically hypothesize that gene and cell therapies can be antiarrhythmic by speeding conduction and/or prolonging refractoriness (but not repolarization) and study these possibilities in the canine heart in situ. Our first two Aims (stated as hypotheses) employ novel approaches to speed conduction. 1: A non-cardiac Na channel that shifts inactivation to more depolarized potentials will enhance Na current density in normal myocytes firing at high rates and preserve Na current density in depolarized myocytes. This should increase action potential (AP) upstroke velocity and conduction velocity, such that antegrade activation is normalized to prevent reentrant arrhythmias and/or the "head" of the activating wave catches the "tail" to terminate reentrant arrhythmias. 2: Increasing diastolic K conductance should restore depolarized membrane potentials towards normal and enhance excitability for normal myocytes at high stimulation frequencies. The third strategy is to prolong the effective refractory period (ERP) with regard to AP duration (APD). 3: Here, we hypothesize that overexpression of a mutant hERG with slowed deactivation kinetics should improve rate responsiveness and prolong ERP compared to APD. This should speed conduction at high heart rates while blocking propagation of premature depolarizations, reducing the likelihood of reentry. The significance of our proposed research is seen in the identification of novel ion channel constructs, testing them via in silico modeling and then in cell experiments to understand and fine-tune mechanism of action; using innovative means to administer them in cell systems and finally in intact animals to treat a reentrant rhythm - ventricular tachycardia - that is a major cause of morbidity and mortality in the US today. The selectivity and specificity of these approaches far exceed those of drugs and of ablation and open promising new vistas for arrhythmia treatment and prevention.
描述(申请人提供):我们建议进行的研究的总体目标是利用我们对折返和心肌梗死相关室性心动过速的病理生理学知识来假设创新的、基于机制的治疗方法我们的一般假设是,以成人间充质干细胞(HMSCs)为平台和/或使用病毒载体的基因治疗可以传递过表达的离子通道基因结构,以预防/抑制这种心律失常。我们提出的五年计划包括:(1)识别和测试特定基因在病毒载体和hMSC平台中过表达的效果,以改变细胞系中特定的离子通道表达;(2)使用数学模型、细胞系统和动物模型来测试我们设计的每个基因和细胞治疗方法的作用机制、有效性和诱发心律失常的潜力。我们特别假设基因和细胞疗法可以通过加速传导和/或延长不稳定(但不是复极)来抗心律失常,并在犬心脏原位研究了这些可能性。我们的前两个目标(作为假设)使用新的方法来加速传导。1:非心源性钠通道使去极化电位的失活转移到更多的去极化电位,将增加正常心肌细胞高频率放电的钠电流密度,并维持去极化心肌细胞的钠电流密度。这应该会增加动作电位(AP)的上搏速度和传导速度,从而使前向激活正常化,以防止折返性心律失常和/或激活波的“头”抓住“尾”以终止折返性心律失常。2.增加舒张期钾电导可使去极化的膜电位恢复正常,增强正常心肌细胞在高刺激频率下的兴奋性。第三种策略是延长AP持续时间的有效不应期(ERP)。3:在这里,我们假设过表达具有缓慢失活动力学的突变的HERG应该比apd更好地提高速率反应和延长ERP。这应该会加快高心率时的传导速度,同时阻止过早去极化的传播,降低再入的可能性。我们拟议的研究的意义在于识别新的离子通道结构,通过电子建模测试它们,然后在细胞实验中了解和微调作用机制;使用创新的方法在细胞系统中使用它们,最后在完整的动物身上治疗折返性心律-室性心动过速-这是当今美国发病率和死亡率的主要原因。这些方法的选择性和特异性远远超过药物和消融术,为心律失常的治疗和预防开辟了新的前景。
项目成果
期刊论文数量(20)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Human embryonic and induced pluripotent stem cell-derived cardiomyocytes exhibit beat rate variability and power-law behavior.
- DOI:10.1161/circulationaha.111.045146
- 发表时间:2012-02-21
- 期刊:
- 影响因子:37.8
- 作者:Mandel Y;Weissman A;Schick R;Barad L;Novak A;Meiry G;Goldberg S;Lorber A;Rosen MR;Itskovitz-Eldor J;Binah O
- 通讯作者:Binah O
Stem cell-based biological pacemakers from proof of principle to therapy: a review.
- DOI:10.1016/j.jcyt.2014.02.014
- 发表时间:2014-07
- 期刊:
- 影响因子:4.5
- 作者:Chauveau, Samuel;Brink, Peter R.;Cohen, Ira S.
- 通讯作者:Cohen, Ira S.
From beat rate variability in induced pluripotent stem cell-derived pacemaker cells to heart rate variability in human subjects.
- DOI:10.1016/j.hrthm.2014.05.037
- 发表时间:2014-10
- 期刊:
- 影响因子:5.5
- 作者:Ben-Ari, Meital;Schick, Revital;Barad, Lili;Novak, Atara;Ben-Ari, Erez;Lorber, Avraham;Itskovitz-Eldor, Joseph;Rosen, Michael R.;Weissman, Amir;Binah, Ofer
- 通讯作者:Binah, Ofer
MATLAB implementation of a dynamic clamp with bandwidth of >125 kHz capable of generating I Na at 37 °C.
- DOI:10.1007/s00424-012-1186-8
- 发表时间:2013-04
- 期刊:
- 影响因子:4.5
- 作者:Clausen, Chris;Valiunas, Virginijus;Brink, Peter R.;Cohen, Ira S.
- 通讯作者:Cohen, Ira S.
The effects of the histone deacetylase inhibitor 4-phenylbutyrate on gap junction conductance and permeability.
- DOI:10.3389/fphar.2013.00111
- 发表时间:2013
- 期刊:
- 影响因子:5.6
- 作者:Kaufman J;Gordon C;Bergamaschi R;Wang HZ;Cohen IS;Valiunas V;Brink PR
- 通讯作者:Brink PR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IRA S COHEN其他文献
IRA S COHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IRA S COHEN', 18)}}的其他基金
A full spectrum rational approach to identify antiarrhythmic agents targeting IKs Channels
识别针对 IK 通道的抗心律失常药物的全谱理性方法
- 批准号:
10734513 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
From human keratinocytes to biological pacemakers
从人类角质形成细胞到生物起搏器
- 批准号:
8795752 - 财政年份:2012
- 资助金额:
$ 73.86万 - 项目类别:
From human keratinocytes to biological pacemakers
从人类角质形成细胞到生物起搏器
- 批准号:
8423701 - 财政年份:2012
- 资助金额:
$ 73.86万 - 项目类别:
From human keratinocytes to biological pacemakers
从人类角质形成细胞到生物起搏器
- 批准号:
8219449 - 财政年份:2012
- 资助金额:
$ 73.86万 - 项目类别:
Novel ion channel approaches to reentrant arrythymias
治疗折返性心律失常的新型离子通道方法
- 批准号:
8274331 - 财政年份:2009
- 资助金额:
$ 73.86万 - 项目类别:
PACEMAKER CURRENTS IN THE DEVELOPING MAMMALIAN HEART
哺乳动物心脏发育中的起搏器电流
- 批准号:
6630020 - 财政年份:2002
- 资助金额:
$ 73.86万 - 项目类别:
PACEMAKER CURRENTS IN THE DEVELOPING MAMMALIAN HEART
哺乳动物心脏发育中的起搏器电流
- 批准号:
6457054 - 财政年份:2001
- 资助金额:
$ 73.86万 - 项目类别:
PACEMAKER CURRENTS IN THE DEVELOPING MAMMALIAN HEART
哺乳动物心脏发育中的起搏器电流
- 批准号:
6335057 - 财政年份:2000
- 资助金额:
$ 73.86万 - 项目类别:
PACEMAKER CURRENTS IN THE DEVELOPING MAMMALIAN HEART
哺乳动物心脏发育中的起搏器电流
- 批准号:
6109643 - 财政年份:1999
- 资助金额:
$ 73.86万 - 项目类别:
PACEMAKER CURRENTS IN THE DEVELOPING MAMMALIAN HEART
哺乳动物心脏发育中的起搏器电流
- 批准号:
6272650 - 财政年份:1998
- 资助金额:
$ 73.86万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 73.86万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 73.86万 - 项目类别: